In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

argenx SE

www.argenx.com

Latest From argenx SE

Finance Watch: Investors Bet Billions On Big Biopharma Offerings

Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.

Financing Business Strategies

Argenx Builds Presence As Efgartigimod Positive In Pivotal Myasthenia Study

The European biotech argenx has reported positive top-line results for its FcRn antagonist efgartigimod in generalized myasthenia gravis in the Phase III ADAPT study, and is planning to market the product itself in the US, Japan and major EU countries.

Clinical Trials Neurology

Finance Watch: As US IPO Market Gets More Challenging, Two Companies Opt Out

Public Company Edition: Five biopharma firms went public in the US in recent weeks, but Inhibrx withdrew its IPO and Monopar postponed its offering. Also, Tot Biopharm launched an IPO in Hong Kong, while Epizyme sold royalties and issued debt to raise up to $270m.

Financing Business Strategies

Genentech Builds Case For Rituxan In Pemphigus With Comparator Study Data

Genentech reports that Rituxan yields better results over 52 weeks in pemphigus patients than off-label use of CellCept. Principia, meanwhile, unveils positive Phase II data for its pemphigus candidate.

Clinical Trials Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Immune Disorders
  • Alias(es)
  • arGEN-X NV
  • arGEN-X BV
  • argenx NV
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Parent & Subsidiaries
  • argenx SE
  • Senior Management
  • Tim Van Hauwermeiren, CEO
    Eric Castaldi, CFO
    Hans de Haard, PhD, CSO
    Torsten Dreier, PhD, Chief Dev. Officer
    Nicolas Leupin, MD, CMO
    Keith Woods, COO
  • Contact Info
  • argenx SE
    Phone: (31) (0) 763 030 488
    Willemstraat 5
    Breda, 4811
    Netherlands
UsernamePublicRestriction

Register